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ABSTRACT
Background and Objectives: The role of preoperative transthoracic echocardiography (TTE) for the risk stratification has 
not been well investigated yet. We compared the predictive power of TTE with N-terminal pro-brain natriuretic peptide (NT-
proBNP), a representative biomarker that predicts perioperative cardiovascular risk, and investigated whether these tests 
have incremental value to the clinically determined risk. Subjects and Methods: We evaluated the Revised Cardiac Risk In-
dex (RCRI), TTE, and NT-proBNP in 1,923 noncardiac surgery cases. The primary endpoint was a perioperative major cardio-
vascular event (PMCE), which was defined by any single or combined event of secondary endpoints including myocardial in-
farction, development of pulmonary edema, or primary cardiovascular death within 30 days after surgery. Results: All echo-
cardiographic parameters including left ventricular ejection fraction, regional wall motion score index, and transmitral early 
diastolic velocity/tissue Doppler mitral annular early diastolic velocity (E/E’) were predictive of PMCE (c-statistics=0.579± 
0.019 to 0.589±0.015), but none of these parameters were better than the clinically determined RCRI (c-statistics=0.594±0.019) 
and were inferior to NT-proBNP (c-statistics=0.748±0.019, p<0.001). The predictive power of RCRI {adjusted relative risk (RR)= 
1.4} could be improved by addition of echocardiographic parameters (adjusted RR=1.8, p<0.001), but not to that extent as by 
addition of NT-proBNP to RCRI (adjusted RR=3.7, p<0.001). Conclusion: TTE was modestly predictive of perioperative 
cardiovascular events but was not superior to NT-proBNP. Moreover, it did not have incremental value to the clinically deter-
mined risk. The results of our study did not support the use of routine echocardiography before noncardiac surgery. (Korean 
Circ J 2011;41:505-511)
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Introduction
Most clinical cardiovascular risk indices are shown to have 
modest predictive power in patients undergoing major non-
cardiac surgery.
1) Preoperative transthoracic echocardiogra-
phy (TTE) is one of non-invasive cardiac evaluation tests that 
are frequently expected to increase the predictive power. Al-
though poor left ventricular (LV) systolic or diastolic function 
is known to be predictive of postoperative heart failure or dea-
th,
2-4) the routine use of preoperative echocardiography in cli-
nically stable patients is not usually recommended by the cur-
rent guidelines.
1)
Recent studies have shown that natriuretic peptides can pre-
dict postoperative cardiovascular events.
5-8) Currently, little 
data is available on the direct comparison of imaging- or bio-
marker-based predictors, or the incremental value of these pre-
dictors to the clinically determined risk. We compared direct-
ly the predictive power of N-terminal pro-brain natriuretic 506   Echocardiography and NT-proBNP for Perioperative Risk Evaluation
peptide (NT-proBNP) with TTE for the postoperative major 
cardiovascular events, and investigated whether additional ev-
aluation of these risk predictors has incremental value to the 
clinical risk stratification.
Subjects and Methods
Study population
The study population was derived from our prospective, un-
selected, consecutive cohort of preoperative cardiac consult-
ation for elective noncardiac surgery.
5) Of the 2,304 cohort 
patients, 1,923 (83.5%) patients had echocardiography with-
in 2 weeks before surgery and constituted the study group (Fig. 
1). Patients with moderate or severe valvular stenosis were not 
included in this study population. This study protocol was ap-
proved by the institutional review board of Samsung Medical 
Center.
Data collection
Clinical perioperative cardiovascular risk was assessed ac-
cording to the Revised Cardiac Risk Index (RCRI) modified 
by Lee, a well-validated and widely used point score-based 
risk prediction index.
9)10) Briefly, RCRI calculates periopera-
tive risk by sum of points. Each risk factor, including high-risk 
surgical procedures, history of ischemic heart disease, pulmo-
nary edema, cerebrovascular disease, insulin-dependent dia-
betes and serum creatinine >2.0 mg/dL, is assigned one point. 
The risk of major cardiac event including myocardial infarc-
tion, pulmonary edema, primary cardiac arrest and complete 
heart block predicted by RCRI was known to be 0.4% to 11% 
according to an RCRI score of 0 to ≥3.
Basic laboratory tests including electrocardiography, chest 
X-ray, and NT-proBNP were evaluated within 2 weeks before 
surgery. Blood samples for NT-proBNP were collected into li-
thium heparin tubes and stored at -70°C until further analy-
sis. Plasma NT-proBNP levels were measured using an Elec-
sys pro-BNP reagent kit (Roche Diagnostics, Indianapolis, In, 
USA) and an Elecsys 2010 analyzer (Roche Diagnostics, India-
napolis, IN, USA).
Transthoracic echocardiography
Two-dimensional (2-D) TTE was performed within 2 weeks 
before surgery at the discretion of the physician or if the pati-
ents had two or more of the following cardiovascular risk fac-
tors: diabetes mellitus, hypertension, aged 65 years or greater, 
current smoking status, or hypercholesterolemia. TTE was 
performed with a commercially available echocardiographic 
instrument (Vivid 7, GE Medical Systems, Milwaukee, WI, 
USA or Sequoia 512, Acuson, Mountain View, CA, USA). A 
standard M-mode, 2-D echocardiogram and echocardiograph-
ic Doppler study were performed. All TTE recordings were 
interpreted by staff cardiologists.
The routine standard echocardiographic examination in-
cluded measurements of thickness of the ventricular septum 
and LV posterior wall, end-systolic and end-diastolic LV dia-
meters from M-mode or 2-D imaging. Left atrial (LA) volume 
measurement and standard pulsed wave Doppler evaluation 
of diastolic function were carried out as previously describ-
ed.
11) Both LV mass and LA volume were indexed to body 
surface area. Mitral inflow velocities were obtained by pu-
lsed wave Doppler sample volume between the mitral leaflet 
tips during diastole and mitral annulus velocities were ob-
Candidates for elective major non-cardiac surgery 
were referred to consulting physician for the preoperative
 evaluation of cardiovascular risk (n=2,304)
Enrolled for registry (n=1,923)
Perioperative major cardiovascular event
(PMCE) occurred in 14.6% (n=280)
Acute myocardial infarction 
in 5.2% (n=100)
Pulmonary edema
in 12.5% (n=241)
Primary cardiovascular
death in 0.7% (n=14)
Surgery was cancelled or not done within 2 weeks (n=118)
Ongoing myocardial ischemia or open heart surgery (n=29)
Creatinine ≥2.0 mg/dL (n=103)
2-D echocardiography within 2 weeks was not available (n=131)
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tained from the septal portion of the mitral annulus by tis-
sue Doppler imaging. All measurements were performed on 
3 cardiac cycles and were then averaged.
Quantitative LV systolic ejection fraction (LVEF) and regio-
nal wall motion index (RWMI) was obtained from the digital-
ly stored records. Diastolic dysfunction could be evaluated in 
a subgroup of 1,132 patients (58.9%) who were examined us-
ing tissue Doppler imaging with acceptable quality, and did 
not have non-sinus rhythm or left bundle branch block.
Clinical outcome
All patients were followed until discharge or up to 30 days 
of hospitalization after surgery. Primary endpoint was a pe-
rioperative major cardiovascular event (PMCE), which was 
defined by any single or combined event of secondary end-
points including myocardial infarction, development of pul-
monary edema, or primary cardiovascular death. Individual 
patients may have had more than one event, and all events were 
counted as an incidence. Myocardial infarction was defined 
by a rise in postoperative troponin I above the 99th percen-
tile of the upper reference limit (0.78 ng/mL, Roche Diag-
nostics, Switzerland), which was evaluated at the end of the 
day of surgery and 24 hours later. Pulmonary edema was di-
agnosed after a formal reading of the chest X-ray by a radio-
logist consistent with the complication. Primary cardiovascu-
lar death was defined by sudden death that could not be ex-
plained by any other non-cardiovascular postoperative com-
plications.
Statistical analysis
Perioperative risk predictors including RCRI, NT-proBNP, 
and echocardiographic parameters were treated as continu-
ous variables or ordered categorical variables. Receiver-op-
erating characteristic (ROC) analysis was performed to cal-
culate sensitivity, specificity, area under the curve (AUC), and 
the optimal cut-off value. The predictive power of each pre-
dictor was compared using Hanley and McNail method.
12) 
Independent predictors of PMCE in univariate analysis were 
categorized by optimal cut-off levels, and were used in mul-
tivariate logistic models.
13) The adjusted relative risk (RR) of 
each predictor and the combination of these predictors in an 
additive manner was evaluated. A p<0.05 (2-sided) was con-
sidered significant. SPSS version 13.0 was used mostly. ROC 
curves were compared using Medcalc version 9.6.
Results
Baseline characteristics
Preoperative clinical characteristics of the study popula-
tion are shown in Table 1. 2-D TTE was performed within 2 
weeks before surgery (10.8±8.2 days). NT-proBNP were ev-
aluated within 2 weeks before surgery (7.4±7.2 days). Briefly, 
Table 1. Clinical characteristics
 
Frequency (%) or median 
with interquartile range
Age (years) 68 (61-73)
Male (sex) 1,185 (61.6)
Functional class III or IV 105 (5.5)
Diabetes* 341 (17.7)
Hypertension 1,162 (60.4)
Previous or current heart failure 62 (3.2)
Previous stroke 182 (9.5)
Angina 256 (13.3)
Previous myocardial infarction 163 (8.5)
Previous revascularization†  296 (15.4)
Pathological Q waves 105 (5.5)
Atrial fibrillation 162 (8.4)
Left bundle branch block 14 (0.7)
Preoperative noninvasive test‡ 752 (39.1)
   Overall positive result for ischemia 185 (9.6)
Preoperative invasive test 534 (27.8)
   Significant coronary artery disease
     by invasive test
353 (18.4)
Any evidence of myocardial ischemia§ 437 (22.7)
Creatinine (mg/dL) 0.90 (0.74-1.06)
NT-proBNP (ng/L) 113 (50-377)
Left ventricular ejection fraction 63 (58-68)
   Left ventricular ejection fraction
     ≤40%
95 (4.9)
Abnormal left ventricular wall motion 407 (21.2)
E/E’ 9.8 (7.6-12.4)
Left atrial volume index 25.4 (18.7-33.0)
RCRI (median, interquartile range) 1 (0-2)
High risk surgery by RCRI¶ 813 (42.3)
Beta blocker 336 (17.5)
ACE inhibitor or ARB 468 (24.3)
Calcium channel blocker 478 (24.9)
Aspirin 496 (25.8)
Statin 290 (15.1)
Nitrate 80 (4.2)
IV inotropic agents 10 (0.5)
*Includes 68 (3.5%) patients with insulin-dependent diabetes, †In-
cludes 215 (11.2%) cases of percutaneous coronary intervention 
and 81 (4.2%) cases of bypass surgery, ‡Includes 647 (33.6%) cases 
in which SPECT was performed, 138 (7.2%) cases in which tread-
mill test was performed, and 45 (2.3%) cases in which stress echo-
cardiography was performed, §Any positive result of non-invasive 
test or significant (>50%) stenosis of major coronary artery by in-
vasive test, ¶Defined as intraperitoneal, intrathoracic, or suprain-
guinal vascular surgery according to the Revised Cardiac Risk In-
dex (RCRI modified by Lee). NT-proBNP: N-terminal pro-brain 
natriuretic peptide, ACE: angiotensin converting enzyme, ARB: 
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most patients had good functional status without overt heart 
failure (functional class I or II in 94.5% and no history of he-
art failure in 96.8%). Evidence of myocardial ischemia which 
was determined by positive non-invasive test or significant 
coronary artery stenosis was found in 22.7%. Percutaneous 
coronary intervention (PCI) or coronary artery bypass sur-
gery (CABG) before surgery had been performed in 15.4%. 
Abnormal LV wall motion and LV systolic dysfunction de-
fined by an ejection fraction of less than 40% was found in 
21.2% of patients. Most patients received general anesthesia 
(97.5%). Patients who underwent urgent surgery within 24 
hours after consultation because of altered clinical situation 
(4.4%) were not excluded from the analysis (Table 2).
Clinical outcomes
PMCE had developed in 280 patients (14.6%), including 
100 (5.0%) acute myocardial infarction, 241 (12.5%) pulmo-
nary edema, and 14 (0.7%) primary cardiovascular deaths 
caused by 3 (0.2%) acute myocardial infarction, 2 (0.1%) st-
ress induced cardiomyopathy, 4 (0.2%) aortic aneurysm rup-
ture or dissection, 1 (0.1%) stroke, and 4 (0.2%) sudden death 
of unknown cause (Fig, 1). There were 5 deaths caused by po-
stoperative disease progression or surgical complication (0.3%). 
There were no differences in PMCE between the vascular 
surgery and non-vascular surgery groups in this study.
Receiver-operating characteristic analysis 
of perioperative risk predictors
ROC analysis using continuous variables showed that all 
Table 2. Surgical procedure
  Frequency (%)
Vascular surgery 523 (27.2)
    Aorta 158 (8.2)0
    Suprainguinal vascular 96 (5.0)0
    Infrainguinal vascular 156 (8.1)0
    Carotid endarterectomy 96 (5.0)0
    Other vascular 17 (0.9)0
Non-vascular surgery 1,400 (72.8)
    Thorax 85 (6.0)0
    Abdomen 474 (33.9)
    Head and neck 154 (11)0.
    Orthopedic 415 (29.6)
    Prostate 78 (5.6)0
    Neurosurgery 36 (2.6)0
    Other surgery 158 (11.3)
General anesthesia 1,874 (97.5)
Urgent surgery 085 (4.4)0
Fig. 2. Comparison of risk predictors. The predictive power of each 
risk predictors for the perioperative major cardiovascular event 
was investigated and compared to each other by area under curve 
(AUC) of ROC analysis. AUC with 95% confidence intervals (CIs) are 
shown. NT-proBNP: N-terminal pro-brain natriuretic peptide, RC-
RI: Revised Cardiac Risk Index, LVEF: left ventricular ejection frac-
tion, RWMI: regional wall motion index, LA volume index: left atrial 
volume index, E/E’: transmitral early diastolic velocity/tissue Dop-
pler mitral annular early diastolic velocity. *p<0.05 by Hanley and 
McNeil method, ROC: receiver-operating characteristic.
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Table 3. Diagnostic performance of risk predictors categorized using optimal cut-off values for the postoperative major cardiovascular event
Optimal cut-off Sensitivity Specificity Positive predictive value Negative predictive value
NT-proBNP ≥301 ng/L  65.0 (59.1-70.6) 77.9 (75.8-79.8) 33.3 (29.4-37.5) 92.9 (91.4-94.2)
RCRI ≥2 49.6 (43.6-55.7) 69.2 (66.9-71.4) 21.6 (18.4-24.9) 89.0 (87.1-90.6)
LVEF <50% 22.9 (18.1-28.2) 92.9 (91.5-94.1) 35.4 (28.4-42.8) 87.6 (86.0-89.1)
E/E’ ≥13 23.6 (18.7-29.0) 86.7 (84.9-88.3) 23.2 (18.4-28.5) 86.9 (85.2-88.5)
LA volume index ≥33 27.1 (22.0-32.8) 83.2 (81.3-85.0) 21.6 (17.4-26.3) 87.0 (85.3-88.6)
Any RWMA exists 36.4 (30.8-42.4) 81.4 (79.5-83.3) 25.1 (20.9-29.6) 88.3 (86.5-89.8)
Any abnormal echocardiographic
  parameters from the above
48.2 (42.2-54.2) 71.6 (69.3-73.7) 22.4 (19.2-26.0) 89.0 (87.2-90.7)
The sensitivity, specificity, positive predictive value, and negative predictive values of each categorized risk predictors are shown. Because 
these values depend on the cut-off levels, values at the point of optimal cut-off levels calculated from ROC analysis were presented. NT-proB-
NP: N-terminal pro-brain natriuretic peptide, RCRI: Revised Cardiac Risk Index, LVEF: left ventricular ejection fraction, LA: Left atrial, 
RWMA: regional wall notion abnormalitySung-Ji Park, et al.   509
echocardiographic parameters including systolic and dia-
stolic parameters were modestly predictive of PMCE; LVEF 
[AUC=0.614 {95% confidence interval (CI)=0.591-0.637}], 
RWM score index {AUC=0.603 (0.580-0.626)}, LA volume in-
dex {AUC=0.593 (0.563-0.623)}, and E/E’ {AUC=0.567 (0.536- 
0.597)} (p<0.05 for all). However, the predictive power of 
these parameters was not higher than RCRI {AUC=0.622 
(0.599-0.644)} (p=0.020 between E/E’, p=not significant be-
tween echocardiographic parameters) and was significantly 
lower than NT-proBNP {AUC=0.748 (0.727-0.768)} (p< 
0.001 between echocardiographic parameters) (Fig. 2).
To evaluate the incremental value of other risk predictors 
to clinical risk index, RR adjusted to age, sex, and traditional 
clinical factors were calculated using the parameters catego-
rized by optimal cut-off levels. The RR of RCRI cut-off (≥2) 
increased 2.8-fold after addition of NT-proBNP cut-off (≥301 
ng/L) {RR=1.4 (95% CI=1.0-1.8) to 3.7 (2.7-5.0), p<0.001}. 
Contrarily, the RR of RCRI cut-off (≥2) modestly increased 
after addition of LVEF cut-off (≤50%) {RR=1.4 (1.0-1.8) to 
1.8 (1.4-2.4), p<0.001} and did not increase after addition of 
all the other echocardiographic parameters. Addition of 
both NT-proBNP and echocardiographic parameters did not 
result in a further increase in RR. The increase in RR by addi-
tion of NT-proBNP to RCRI was also evident in secondary 
endpoints including AMI and pulmonary edema (Table 4).
Discussion
To our knowledge, this is the first study to compare the pre-
dictive power of hemodynamic biomarker with that of imag-
ing modality and investigated the incremental value of these 
modalities to the clinically determined risk. TTE, which is 
one of the widely used cardiovascular imaging modality, was 
inferior to NT-proBNP, a representative hemodynamic bio-
marker, for the prediction of perioperative cardiovascular 
risk in non high-risk patients for major noncardiac surgery. 
Moreover, TTE did not have incremental value to the clini-
cally determined risk whereas NT-proBNP had incremental 
value to the clinically determined risk.
Most preoperative echocardiographic assessments have 
focused on the systolic function. Decreased LV ejection frac-
tion has been repeatedly shown to be associated with periop-
erative cardiovascular morbidity.
2)3)14)15) In our study, LVEF 
of less than 50% was significantly but modestly predictive of 
PMCE. Although diastolic dysfunction is not uncommon in 
patients undergoing noncardiac surgery, routine preopera-
tive evaluation does not include evaluation of diastolic dys-
function for risk stratification. In our study, the presence of 
perioperative diastolic dysfunction was not related to the pe-
rioperative cardiovascular risk. The result of our study could 
be partially explained by the difference between a general 
cardiovascular biomarker and an imaging modality. NT-
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s510   Echocardiography and NT-proBNP for Perioperative Risk Evaluation
proBNP is one of best independent predictors of cardiovas-
cular impairment as well as a marker of myocardial ischemia 
and heart failure, which might better reflect the complex 
pathophysiology of perioperative cardiovascular stress rep-
resented by a catecholamine surge with associated hemody-
namic stress, systemic inflammation, and hypercoagulabili-
ty.
16-18) On the other hand, E/E’ is a specific marker for LV fill-
ing pressure which could be affected significantly by perio-
perative volume status.
19)
Integration of both NT-proBNP and echocardiographic pa-
rameters modestly improved the predictive power of the cli-
nically determined risk, except for the risk of primary cardio-
vascular death {RR=5.3 (95% CI=1.1-25.9), p=0.041}. There-
fore, these two risk predictors might provide complementary 
prediction in the high-risk event or death.
18) Investigation of 
the role of preoperative echocardiography in the high-risk 
group and comparison with biomarkers would be advisable 
in the near future.
16)
Our study is not free from its several limitations as de-
scribed below. First, in our patient cohort, only 4.9% of pa-
tients had abnormal LV systolic function (LVEF <40%) and pa-
tient mean age was 68 years. All patients in our study were 
low-risk non high-risk patients for major noncardiac surgery. 
Therefore, these characteristics may limit the generalizability 
of our findings. Secondly, only patients who had undergone 
formal preoperative cardiovascular consultation were includ-
ed. Thirdly, NT-proBNP and echocardiography were not ev-
aluated on the same day. Fourthly, tissue Doppler study was 
done in only 59% of patients due to financial and clinical con-
straints. However, given the strength of our results, it is un-
likely that enrollment of more patients or tissue Doppler study 
in more number of patients would have changed the main re-
sults of our study. Although it has been well validated and 
widely used in clinical practice, only the transmitral early dia-
stolic velocity/tissue Doppler mitral annular early diastolic 
velocity (E/E’) has been used for the evaluation of diastolic 
dysfunction. The recently developed new methods for the ev-
aluation of diastolic dysfunction such as strain, strain rate and 
LV torsion have not been evaluated and would be of interest 
in future studies.
In conclusion, preoperative echocardiography was modest-
ly predictive of perioperative cardiovascular events but was 
inferior to NT-proBNP. Moreover, it did not have incremen-
tal value to the clinically determined risk. Our results did not 
support the use of routine evaluation of echocardiography be-
fore noncardiac surgery. However, preoperative echocardio-
graphy before noncardiac surgery can provide independent 
information about the risk of postoperative cardiac complica-
tions in selected patients.
Acknowledgments
This study was supported by grants from the Samsung Medical Center 
Clinical Research Development Program, the In-Sung Foundation for 
Medical Research and a grant from the Korean Society of Cardiology 
(Industrial-Educational Cooperation, 2005).
REFERENCES
1) Fleisher LA, Beckman JA, Brown KA, et al. 2009 ACCF/AHA fo-
cused update on perioperative beta blockade incorporated into the 
ACC/AHA 2007 guidelines on perioperative cardiovascular evalua-
tion and care for noncardiac surgery. J Am Coll Cardiol 2009;54: 
e13-118.
2) Halm EA, Browner WS, Tubau JF, Tateo IM, Mangano DT. Echo-
cardiography for assessing cardiac risk in patients having noncardiac 
surgery. Study of Perioperative Ischemia Research Group. Ann Intern 
Med 1996;125:433-41.
3) Rohde LE, Polanczyk CA, Goldman L, Cook EF, Lee RT, Lee TH. 
Usefulness of transthoracic echocardiography as a tool for risk strati-
fication of patients undergoing major noncardiac surgery. Am J Car-
diol 2001;87:505-9.
4) Kertai MD, Poldermans D, Bax JJ, Klein J, Van Urk H. Cardiac risk 
and perioperative management. J Cardiovasc Surg (Torino) 2003; 
44:431-5.
5) Choi JH, Cho DK, Song YB, et al. Preoperative NT-proBNP and CRP 
predict perioperative major cardiovascular events in non-cardiac 
surgery. Heart 2010;96:56-62.
6) Feringa HH, Bax JJ, Elhendy A, et al. Association of plasma N-termi-
nal pro-B-type natriuretic peptide with postoperative cardiac events in 
patients undergoing surgery for abdominal aortic aneurysm or leg by-
pass. Am J Cardiol 2006;98:111-5.
7) Yun KH, Jeong MH, Oh SK, et al. Preoperative plasma N-terminal 
pro-brain natriuretic peptide concentration and perioperative cardio-
vascular risk in elderly patients. Circ J 2008;72:195-9.
8) Karthikeyan G, Moncur RA, Levine O, et al. Is a pre-operative brain 
natriuretic peptide or N-terminal pro-B-type natriuretic peptide mea-
surement an independent predictor of adverse cardiovascular out-
comes within 30 days of noncardiac surgery? A systematic review and 
meta-analysis of observational studies. J Am Coll Cardiol 2009;54: 
1599-606.
9) Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and pro-
spective validation of a simple index for prediction of cardiac risk of 
major noncardiac surgery. Circulation 1999;100:1043-9.
10)   Devereaux PJ, Goldman L, Cook DJ, Gilbert K, Leslie K, Guyatt GH. 
Perioperative cardiac events in patients undergoing noncardiac sur-
gery: a review of the magnitude of the problem, the pathophysiology 
of the events and methods to estimate and communicate risk. CMAJ 
2005;173:627-34.
11)   Lang RM, Bierig M, Devereux RB, et al. Recommendations for 
chamber quantification: a report from the American Society of Echo-
cardiography’s Guidelines and Standards Committee and the Cham-
ber Quantification Writing Group, developed in conjunction with the 
European Association of Echocardiography, a branch of the Europe-
an Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63.
12)   Stephan C, Wesseling S, Schink T, Jung K. Comparison of eight com-
puter programs for receiver-operating characteristic analysis. Clin 
Chem 2003;49:433-9.
13) Zhang J, Yu KF. What’s the relative risk? A method of correcting the 
odds ratio in cohort studies of common outcomes. JAMA 1998;280: 
1690-1.
14)   Kontos MC, Brath LK, Akosah KO, Mohanty PK. Cardiac complic-
ations in noncardiac surgery: relative value of resting two-dimensional 
echocardiography and dipyridamole thallium imaging. Am Heart J 
1996;132:559-66.
15) Takase B, Younis LT, Byers SL, et al. Comparative prognostic value of 
clinical risk indexes, resting two-dimensional echocardiography, and 
dipyridamole stress thallium-201 myocardial imaging for periopera-
tive cardiac events in major nonvascular surgery patients. Am Heart 
J 1993;126:1099-106.Sung-Ji Park, et al.   511
16) Struthers A, Lang C. The potential to improve primary prevention in 
the future by using BNP/N-BNP as an indicator of silent ‘pancardiac’ 
target organ damage: BNP/N-BNP could become for the heart what mi-
croalbuminuria is for the kidney. Eur Heart J 2007;28:1678-82.
17)   Poldermans D, Hoeks SE, Feringa HH. Pre-operative risk assess-
ment and risk reduction before surgery. J Am Coll Cardiol 2008;51: 
1913-24.
18)   Schouten O, Bax JJ, Poldermans D. Preoperative cardiac risk as-
sessment in vascular surgery patients: seeing beyond the perioperative 
period. Eur Heart J 2008;29:283-4.
19)   Dokainish H, Zoghbi WA, Lakkis NM, Quinones MA, Nagueh SF. 
Comparative accuracy of B-type natriuretic peptide and tissue Dop-
pler echocardiography in the diagnosis of congestive heart failure. Am 
J Cardiol 2004;93:1130-5.